Back Phelan, M (30 May 2024) 'Winning researchers unlocked GLP-1 drugs for obesity', Science , 384/6699
In contrast, later in 2023, a multisociety statement from gastroenterology and hepatology organizations, including the AGA, AASLD, ACG, ASGE, and NASPGHAN, advised against routine discontinuation of GLP-1 therapy, emphasizing individualized patient management and the use of point-of-care gastric ultrasound (POCUS) to assess aspiration risk [9]
Esto resulta en baja biodisponibilidad y desafos para alcanzar concentraciones teraputicas efectivas comparables a las inyecciones
A subscription model, in which states agree to cover at least a certain number of treatments at a price negotiated with the manufacturer, is the approach Louisiana adopted to pay for curative hepatitis C treatment for as many as 40,000 residents covered by Medicaid